Monique Spillman
Concepts (262)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 17 | 2023 | 459 | 1.840 |
Why?
| | Endometrial Neoplasms | 5 | 2015 | 144 | 0.840 |
Why?
| | Gynecology | 5 | 2020 | 52 | 0.810 |
Why?
| | Genital Neoplasms, Female | 2 | 2020 | 48 | 0.750 |
Why?
| | Gene Expression Regulation, Neoplastic | 10 | 2019 | 857 | 0.740 |
Why?
| | Cystadenocarcinoma, Serous | 4 | 2021 | 73 | 0.700 |
Why?
| | Infection Control | 1 | 2020 | 47 | 0.660 |
Why?
| | Ethics, Medical | 1 | 2020 | 43 | 0.660 |
Why?
| | Communication | 1 | 2020 | 257 | 0.590 |
Why?
| | Conflict of Interest | 3 | 2016 | 26 | 0.580 |
Why?
| | Uterus | 1 | 2018 | 88 | 0.570 |
Why?
| | Medical Oncology | 3 | 2020 | 104 | 0.560 |
Why?
| | Robotics | 2 | 2014 | 43 | 0.550 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 178 | 0.540 |
Why?
| | Peptides | 3 | 2015 | 223 | 0.540 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.530 |
Why?
| | Receptors, Estrogen | 5 | 2017 | 131 | 0.530 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 6 | 0.510 |
Why?
| | Fallopian Tube Neoplasms | 2 | 2013 | 15 | 0.500 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 53 | 0.480 |
Why?
| | Pandemics | 1 | 2020 | 585 | 0.480 |
Why?
| | Glycoproteins | 1 | 2015 | 122 | 0.480 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2014 | 28 | 0.470 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 99 | 0.460 |
Why?
| | Antigens, CD | 1 | 2015 | 218 | 0.450 |
Why?
| | Adenocarcinoma | 2 | 2015 | 405 | 0.450 |
Why?
| | Salpingectomy | 1 | 2013 | 6 | 0.410 |
Why?
| | Female | 34 | 2023 | 28171 | 0.410 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 13 | 0.410 |
Why?
| | General Surgery | 1 | 2014 | 105 | 0.410 |
Why?
| | Peritoneal Neoplasms | 2 | 2011 | 65 | 0.410 |
Why?
| | MicroRNAs | 4 | 2021 | 387 | 0.400 |
Why?
| | Estrogens | 2 | 2012 | 223 | 0.400 |
Why?
| | Clinical Trials as Topic | 2 | 2007 | 467 | 0.380 |
Why?
| | Medicare Part B | 1 | 2011 | 5 | 0.380 |
Why?
| | Professional Corporations | 1 | 2011 | 1 | 0.380 |
Why?
| | Marketing of Health Services | 1 | 2011 | 7 | 0.370 |
Why?
| | Reimbursement Mechanisms | 1 | 2011 | 24 | 0.370 |
Why?
| | Physicians | 2 | 2016 | 241 | 0.370 |
Why?
| | Social Responsibility | 1 | 2011 | 25 | 0.370 |
Why?
| | Receptors, Progesterone | 4 | 2015 | 66 | 0.360 |
Why?
| | Cell Line, Tumor | 11 | 2016 | 1470 | 0.360 |
Why?
| | Trust | 1 | 2011 | 63 | 0.360 |
Why?
| | Carcinoma, Large Cell | 1 | 2010 | 17 | 0.350 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2010 | 25 | 0.350 |
Why?
| | Humans | 42 | 2023 | 52483 | 0.350 |
Why?
| | Health Care Reform | 1 | 2010 | 22 | 0.340 |
Why?
| | Interprofessional Relations | 1 | 2011 | 90 | 0.340 |
Why?
| | Physician-Patient Relations | 1 | 2011 | 143 | 0.330 |
Why?
| | Breast Neoplasms | 4 | 2012 | 1212 | 0.320 |
Why?
| | Uterine Neoplasms | 2 | 2019 | 60 | 0.290 |
Why?
| | Transplantation, Heterologous | 2 | 2012 | 79 | 0.290 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2010 | 299 | 0.280 |
Why?
| | Physician's Role | 2 | 2011 | 49 | 0.280 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2007 | 29 | 0.270 |
Why?
| | Apoptosis | 5 | 2016 | 1119 | 0.270 |
Why?
| | Genes, Tumor Suppressor | 1 | 2007 | 74 | 0.260 |
Why?
| | Advance Directives | 1 | 2007 | 29 | 0.260 |
Why?
| | Patient Dropouts | 1 | 2007 | 51 | 0.260 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 179 | 0.250 |
Why?
| | Claudin-4 | 2 | 2016 | 7 | 0.240 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2005 | 29 | 0.240 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1031 | 0.230 |
Why?
| | Ovary | 1 | 2004 | 107 | 0.220 |
Why?
| | Hysterectomy | 2 | 2014 | 90 | 0.220 |
Why?
| | Epithelial Cells | 1 | 2004 | 215 | 0.210 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2017 | 582 | 0.210 |
Why?
| | Aged | 11 | 2021 | 10121 | 0.200 |
Why?
| | Neoplasm Staging | 4 | 2021 | 772 | 0.190 |
Why?
| | Middle Aged | 12 | 2021 | 13028 | 0.190 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1105 | 0.190 |
Why?
| | Cisplatin | 2 | 2015 | 285 | 0.180 |
Why?
| | Immunohistochemistry | 6 | 2017 | 979 | 0.170 |
Why?
| | Cell Movement | 3 | 2016 | 268 | 0.170 |
Why?
| | Resource Allocation | 1 | 2020 | 14 | 0.170 |
Why?
| | Standard of Care | 1 | 2020 | 17 | 0.170 |
Why?
| | Disclosure | 2 | 2016 | 41 | 0.170 |
Why?
| | Loss of Heterozygosity | 2 | 2013 | 78 | 0.170 |
Why?
| | Lymphatic Metastasis | 2 | 2010 | 220 | 0.160 |
Why?
| | Leiomyosarcoma | 1 | 2019 | 21 | 0.160 |
Why?
| | Leiomyoma | 1 | 2019 | 23 | 0.160 |
Why?
| | Neoplasm Invasiveness | 3 | 2015 | 278 | 0.160 |
Why?
| | Early Detection of Cancer | 1 | 2021 | 189 | 0.160 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2012 | 220 | 0.150 |
Why?
| | RNA-Binding Proteins | 2 | 2019 | 128 | 0.150 |
Why?
| | Informed Consent | 3 | 2004 | 95 | 0.150 |
Why?
| | Death | 1 | 2018 | 23 | 0.150 |
Why?
| | Living Donors | 1 | 2018 | 27 | 0.150 |
Why?
| | Critical Care | 1 | 2020 | 222 | 0.150 |
Why?
| | Neoplasms, Glandular and Epithelial | 2 | 2015 | 41 | 0.150 |
Why?
| | Palliative Care | 1 | 2020 | 214 | 0.140 |
Why?
| | Carcinosarcoma | 1 | 2017 | 18 | 0.140 |
Why?
| | Microfilament Proteins | 1 | 2017 | 43 | 0.140 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 100 | 0.130 |
Why?
| | United States | 4 | 2016 | 5192 | 0.130 |
Why?
| | Mice, Nude | 3 | 2012 | 265 | 0.130 |
Why?
| | Industry | 1 | 2016 | 16 | 0.130 |
Why?
| | Adult | 7 | 2021 | 14161 | 0.130 |
Why?
| | Keratin-5 | 1 | 2015 | 2 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2017 | 313 | 0.120 |
Why?
| | Receptors, Androgen | 1 | 2015 | 46 | 0.120 |
Why?
| | Cell Count | 1 | 2015 | 149 | 0.120 |
Why?
| | Cell Proliferation | 4 | 2015 | 1023 | 0.120 |
Why?
| | Prognosis | 4 | 2017 | 2099 | 0.120 |
Why?
| | Neoplasm Seeding | 1 | 2014 | 4 | 0.120 |
Why?
| | Genetic Privacy | 2 | 2004 | 3 | 0.110 |
Why?
| | Alanine | 1 | 2014 | 44 | 0.110 |
Why?
| | Triazines | 1 | 2014 | 26 | 0.110 |
Why?
| | Endometrium | 1 | 2014 | 43 | 0.110 |
Why?
| | Genes, BRCA2 | 1 | 2013 | 13 | 0.110 |
Why?
| | Genes, BRCA1 | 1 | 2013 | 19 | 0.100 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2013 | 24 | 0.100 |
Why?
| | Mice | 6 | 2016 | 5949 | 0.100 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2012 | 7 | 0.100 |
Why?
| | Health Care Costs | 2 | 2013 | 174 | 0.100 |
Why?
| | DNA Methylation | 3 | 2023 | 592 | 0.100 |
Why?
| | Risk Reduction Behavior | 1 | 2013 | 58 | 0.100 |
Why?
| | Carcinoma, Lobular | 1 | 2012 | 32 | 0.100 |
Why?
| | DNA-Binding Proteins | 2 | 2013 | 422 | 0.100 |
Why?
| | Paclitaxel | 1 | 2012 | 89 | 0.100 |
Why?
| | Lymph Nodes | 1 | 2014 | 258 | 0.100 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 28 | 0.100 |
Why?
| | Judicial Role | 1 | 2011 | 6 | 0.100 |
Why?
| | Coercion | 1 | 2011 | 9 | 0.090 |
Why?
| | Medicare Payment Advisory Commission | 1 | 2011 | 2 | 0.090 |
Why?
| | Personal Autonomy | 1 | 2011 | 15 | 0.090 |
Why?
| | Women | 1 | 2011 | 30 | 0.090 |
Why?
| | Prejudice | 1 | 2011 | 37 | 0.090 |
Why?
| | Homeodomain Proteins | 1 | 2012 | 80 | 0.090 |
Why?
| | Politics | 1 | 2011 | 28 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2013 | 187 | 0.090 |
Why?
| | Violence | 1 | 2011 | 62 | 0.090 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2011 | 5 | 0.090 |
Why?
| | Taxoids | 1 | 2011 | 37 | 0.090 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2010 | 23 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2010 | 137 | 0.090 |
Why?
| | Organ Specificity | 1 | 2010 | 115 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2012 | 1132 | 0.090 |
Why?
| | Obstetrics | 1 | 2011 | 89 | 0.090 |
Why?
| | Models, Statistical | 1 | 2011 | 230 | 0.080 |
Why?
| | Cesarean Section | 1 | 2011 | 184 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2014 | 649 | 0.080 |
Why?
| | Alcohol Drinking | 1 | 2011 | 237 | 0.080 |
Why?
| | Blotting, Western | 1 | 2010 | 590 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 405 | 0.080 |
Why?
| | Societies, Medical | 1 | 2010 | 200 | 0.080 |
Why?
| | Transfection | 2 | 2012 | 357 | 0.080 |
Why?
| | Phosphorylation | 2 | 2008 | 528 | 0.080 |
Why?
| | Animals | 6 | 2016 | 13505 | 0.070 |
Why?
| | Aging | 1 | 2013 | 701 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2021 | 3392 | 0.070 |
Why?
| | Alleles | 2 | 2006 | 276 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2014 | 1201 | 0.070 |
Why?
| | Chimera | 1 | 2007 | 10 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 1222 | 0.070 |
Why?
| | CpG Islands | 1 | 2007 | 121 | 0.070 |
Why?
| | MAP Kinase Signaling System | 1 | 2007 | 121 | 0.060 |
Why?
| | Genomic Imprinting | 1 | 2006 | 12 | 0.060 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2006 | 18 | 0.060 |
Why?
| | RNA, Untranslated | 1 | 2006 | 14 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2010 | 436 | 0.060 |
Why?
| | Base Sequence | 1 | 2007 | 640 | 0.060 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 778 | 0.060 |
Why?
| | Repetitive Sequences, Amino Acid | 1 | 2005 | 1 | 0.060 |
Why?
| | Models, Biological | 2 | 2008 | 735 | 0.060 |
Why?
| | North Carolina | 1 | 2005 | 56 | 0.060 |
Why?
| | Databases, Nucleic Acid | 1 | 2004 | 10 | 0.060 |
Why?
| | Carcinoma | 1 | 2006 | 138 | 0.060 |
Why?
| | Telomerase | 1 | 2004 | 26 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2007 | 467 | 0.060 |
Why?
| | RNA Interference | 2 | 2016 | 181 | 0.060 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 213 | 0.060 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 185 | 0.060 |
Why?
| | Tumor Burden | 2 | 2016 | 136 | 0.060 |
Why?
| | Cell Survival | 2 | 2016 | 612 | 0.060 |
Why?
| | Family Health | 1 | 2004 | 79 | 0.050 |
Why?
| | Genetic Counseling | 1 | 2004 | 43 | 0.050 |
Why?
| | Genomics | 1 | 2004 | 268 | 0.050 |
Why?
| | Epigenesis, Genetic | 1 | 2006 | 406 | 0.050 |
Why?
| | Researcher-Subject Relations | 1 | 2002 | 1 | 0.050 |
Why?
| | Ethical Review | 1 | 2002 | 2 | 0.050 |
Why?
| | Contract Services | 1 | 2002 | 13 | 0.050 |
Why?
| | Financial Support | 1 | 2002 | 3 | 0.050 |
Why?
| | Health Care Sector | 1 | 2002 | 15 | 0.050 |
Why?
| | Mice, SCID | 2 | 2012 | 182 | 0.050 |
Why?
| | Biotechnology | 1 | 2002 | 15 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2005 | 528 | 0.050 |
Why?
| | Cell Line | 1 | 2004 | 1030 | 0.050 |
Why?
| | Drug Industry | 1 | 2002 | 40 | 0.050 |
Why?
| | Research Support as Topic | 1 | 2002 | 44 | 0.050 |
Why?
| | Research Subjects | 1 | 2002 | 52 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 126 | 0.040 |
Why?
| | Patient Selection | 1 | 2002 | 259 | 0.040 |
Why?
| | Cooperative Behavior | 1 | 2002 | 227 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2019 | 11 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 48 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 65 | 0.040 |
Why?
| | Risk Assessment | 1 | 2023 | 1327 | 0.040 |
Why?
| | Biomedical Research | 1 | 2002 | 256 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 169 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 891 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 1542 | 0.030 |
Why?
| | Caspase 3 | 1 | 2016 | 95 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 46 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2021 | 6607 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1046 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2015 | 57 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2015 | 229 | 0.030 |
Why?
| | Prospective Studies | 1 | 2021 | 2481 | 0.030 |
Why?
| | Exosomes | 1 | 2015 | 58 | 0.030 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2014 | 10 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2014 | 8 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 184 | 0.030 |
Why?
| | Risk Factors | 2 | 2014 | 3889 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 182 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2014 | 460 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 326 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2013 | 64 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2013 | 66 | 0.030 |
Why?
| | Homologous Recombination | 1 | 2013 | 41 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2013 | 82 | 0.030 |
Why?
| | Karyotyping | 1 | 2012 | 78 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 2013 | 69 | 0.030 |
Why?
| | Anoikis | 1 | 2012 | 8 | 0.030 |
Why?
| | Transduction, Genetic | 1 | 2012 | 44 | 0.030 |
Why?
| | Tubulin | 1 | 2012 | 21 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 706 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 92 | 0.020 |
Why?
| | Tamoxifen | 1 | 2012 | 60 | 0.020 |
Why?
| | Signal Transduction | 2 | 2011 | 1671 | 0.020 |
Why?
| | DNA Fingerprinting | 1 | 2012 | 61 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2012 | 163 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2012 | 36 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 578 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 22 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 221 | 0.020 |
Why?
| | Estradiol | 1 | 2012 | 214 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 1478 | 0.020 |
Why?
| | Microtubules | 1 | 2011 | 39 | 0.020 |
Why?
| | Cell Cycle Checkpoints | 1 | 2011 | 32 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 618 | 0.020 |
Why?
| | Mitosis | 1 | 2011 | 88 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 401 | 0.020 |
Why?
| | HeLa Cells | 1 | 2011 | 265 | 0.020 |
Why?
| | Disease Progression | 1 | 2012 | 871 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 1567 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2011 | 1026 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2008 | 5 | 0.020 |
Why?
| | Progesterone | 1 | 2008 | 58 | 0.020 |
Why?
| | Mutation | 1 | 2013 | 1347 | 0.020 |
Why?
| | Protein Kinases | 1 | 2008 | 72 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2008 | 460 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2008 | 187 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2006 | 122 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 146 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 242 | 0.020 |
Why?
| | Binding Sites | 1 | 2006 | 377 | 0.010 |
Why?
| | Repressor Proteins | 1 | 2006 | 155 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 2680 | 0.010 |
Why?
| | Truth Disclosure | 1 | 2004 | 16 | 0.010 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 24 | 0.010 |
Why?
| | Male | 1 | 2011 | 26761 | 0.010 |
Why?
|
|
Spillman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People  People who share similar concepts with this person. _
|